Matsumara A, Mori T
Department of Surgery, National Kinki-Chuo Hospital for Chest Diseases, 1180 Nagasone-Chou, Sakai-City, Osaka 591-8555, Japan.
Gan To Kagaku Ryoho. 2001 Nov;28(12):1826-32.
Induction therapy for non-small cell lung cancer was reviewed. Surgical therapy remains the treatment of choice for resectable non-small cell lung cancer. However, postoperative survival of the patients with locally advanced NSCLC is far from acceptable. Several phase II and phase III trials have been attempted to define whether surgical resection after induction therapy provides better local control and survival than surgery alone. Most studies have reported high response and resectability rates, and long-term follow up of two randomized trials shows that patients having cisplatin-based induction chemotherapy prior to surgical resection were significantly more likely to have better 5-year survival than patients operated without preoperative treatment. However, the results of the randomized trials are still controversial owing to the relatively small and inhomogeneous population used. To identify the future direction of effort in improving the therapy of NSCLC, more sophisticated randomized prospective trials should be conducted.
对非小细胞肺癌的诱导治疗进行了综述。手术治疗仍然是可切除非小细胞肺癌的首选治疗方法。然而，局部晚期非小细胞肺癌患者的术后生存率远不能令人满意。已经进行了几项II期和III期试验，以确定诱导治疗后手术切除是否比单纯手术能提供更好的局部控制和生存率。大多数研究报告了较高的缓解率和可切除率，两项随机试验的长期随访表明，手术切除前接受基于顺铂的诱导化疗的患者比未接受术前治疗而进行手术的患者更有可能获得更好的5年生存率。然而，由于所使用的人群相对较小且不均一，随机试验的结果仍存在争议。为了确定改善非小细胞肺癌治疗的未来努力方向，应该进行更复杂的随机前瞻性试验。
